Nivolumab in the Treatment of Advanced Renal Cell Carcinoma

Oncology in Clinical Practice - Poland
doi 10.5603/ocp.2018.0040
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

VM Media SP. zo.o VM Group SK

Related search

Re: Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma

European Urology
Urology
2016English

Nivolumab in Treatment of Renal Cell Carcinoma During Renal Replacement Therapy

Oncology in Clinical Practice
Oncology
2019English

Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn136 - A Cost-Effectiveness Analysis of Nivolumab in Combination With Ipilimumab for the Treatment of Advanced Renal Cell Carcinoma in Canada

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Profile of Temsirolimus in the Treatment of Advanced Renal Cell Carcinoma

OncoTargets and Therapy
OncologyPharmacology
2010English

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2016English

M-Tor Inhibitors in the Treatment of Advanced Renal Cell Carcinoma

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2011English

Economic Evaluation of Nivolumab as a Second-Line Treatment for Advanced Renal Cell Carcinoma From US and Chinese Perspectives

Cancer
Cancer ResearchOncology
2017English

Clinical Experience With Temsirolimus in the Treatment of Advanced Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy